Equity Profile

SYRE

Spyre Therapeutics, Inc.

Health CareBiotechnology$6.4B

May8Thu

Post-Earnings Recap

ReportedQ1-2025After Close4:05 PM EDT

Spyre Therapeutics, Inc. Beats on EPS, Stock Up 1.18%

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	+21.26%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

Spyre Therapeutics, Inc. Beats on EPS, Stock Up 1.18%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	+21.26%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Spyre Therapeutics reported a narrower loss than expected, leading to a positive stock reaction with a 1.18% increase. However, the lack of revenue data and management commentary leaves uncertainty about the company's overall performance and future direction.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May5

PLTRReported

Palantir Technologies Inc.

Congress activity

RecapView

Spyre Therapeutics, Inc. Beats on EPS, Stock Up 1.18%

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	+21.26%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

Spyre Therapeutics, Inc. Beats on EPS, Stock Up 1.18%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	+21.26%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime